___

• Ahmed, R.L., Thomas, W., Schmitz, K.H. (2007). Interactions between insulin, body fat, and insulin-like growth factor axis proteins. Cancer Epidemiology Biomarkers and Prevention, 16, 593-597.
• Ahmed, S., Yamamoto, K., Sato, Y., Ogawa, T., Herrmann, A., Higashi, S., et al. (2003). Proteolytic processing of IGFBP-related protein-1 (TAF/angio- modulin/mac25) modulates its biological activity. Biochemical and Biophysical Research Communications, 310, 612-618.
• Amoui, M., Craddock, B.P., Miller, W.T. (2001). Differential phosphorylation of IRS-1 by insulin and insulin-like growth factor I receptors in Chinese hamster ovary cells. Journal of Endocrinology, 171,153–162.
• Bach, L.A., Hsieh, S., Sakano, K., Fujiwara, H., Perdue, J.F., Rechler, M.M. (1993). Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6. Journal of Biological Chemistry, 268, 9246-9254.
• Baxter, R.C., Holman, S.R., Corbould, A. (1995).Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia. Journal of Clininical Endocrinology Metabolism, 80, 2700–2708.
• Baxter, R.C., Martin, J.L., Beniac, V.A. (1989). High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum. Journal of Biological Chemistry, 264, 11843-11848.
• Bienvenu, G., Seurin, D., Le Bouc, Y., Even, P., Babajko, S., Magnan, C. (2005). Dysregulation of energy homeostasis in mice overexpressing insulin-like growth factor-binding protein 6 in the brain. Diabetologia ,48 ,1189e1197.
• Blat, C., Villaudy, J., Binoux, M. (1994). In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. Journal of Clinical Invesigation, 93, 2286–2290. Böni-Schnetzler, M., Schmid, C., Mary, J.L., Zimmerli, B., Meier, P., Zapf, J., et al.(1990). Insulin regulates the expression of the insulin-like growth factor binding protein 2 mRNA in rat hepatocytes. Molecular Endocrinology, 4, 1320-1326
• Boonen, S., Rosen, C., Bouillon, R. (2002). Muskuloskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture, a double blind, placebo-controlled pilot study. The Journal of Clinical Endocrinology Metabolism, 87, 1593–1599.
• Chahal, J., Chen, C.-C., Rane, M.J., Moore, J., Barati, M., Song, Y., et al. (2008). Regulation of insulin-response element binding protein-1 in obesity and diabetes, potential role in impaired insulin-induced gene transcription. Endocrinology, 149, 4829- 4836.
• Clemmons, D.R. (2016). Role of IGF Binding Proteins in Regulating Metabolism. Trends in Endocrinology & Metabolism, 27, 375-391.
• Clemmons, D.R., Moses, A.C., Mckay ,M.J., Sommer, A., Rosen, D.M., Ruckle, J. (2000). The Combination of Insulin-Like Growth Factor I and Insulin-Like Growth Factor-Binding Protein-3 Reduces Insulin Requirements in Insulin-Dependent Type 1Diabetes, Evidence for in Vivo Biological Activity. The Journal of Clinical Endocrinology Metabolism, 85, 1518-1524.
• Daughaday, W.H., Kapadia, M. (1989). Significance of abnormal serum binding of insulin- like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. Proceedings of the National Academy of Sciences, 86, 778–6782.
• Davenport, M.L., Isley, W.L., Pucilowska, J.B. (1992). Insulin-like growth factor-binding protein-3 proteolysis is induced after elective surgery. The Journal of Clinical Endocrinology Metabolism, 75, 590–595.
• Daza, D.O., Sundstrom, G., Bergqvist, C.A., Duan, C., Larhammar, D. (2011). Evolution of the insulin-like growth factor binding protein (IGFBP) family. Endocrinology, 152, 2278–2289.
• Durham, S.K., Mohan, S., Liu, F. (1997). Bioactivity of a 29-kilodalton insulin-like growth factor binding protein-3 fragment present in excess in chronic renal failure serum. Pediatric Research, 42, 335–341.
• Firth, S.M., Baxter, R.C. (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocrine Reviews, 23, 824–854.
• Friedrich, N et al. (2014). Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays. The Journal of Clinical Endocrinology Metabolism, 99, 1675–1686.
• Gederet ,Y.T., Öztürk, B., Karagözoğlu, E., Gök, M., Tiftik, A.M. (2004). Malign-Nonmalign plevral efüzyon ayırıcı tanısında IGF ve IGFBP’lerin rolü. Genel Tıp Dergisi, 14,139-143.
• Gleason, C.E., Ning, Y., Cominski, T.P., Kaestner, K.H., Pintar, J.E., Birnbaum, M.J. (2010). Role of insulin-like growth factor-binding protein 5 (IGFBP5) in organismal and pancreatic beta-cell growth. Molecular Endocrinology, 24,178-192.
• Gu, H.F., Gu, T., Hilding, A., Zhu, Z., Kärvestedt, L., Östenson, C., et al. (2013). Evaluation of IGFBP-7 DNA methylation changes and serum protein variation in Swedish subjects with and without type 2 diabetes. Clinical Epigentics, 5, 1-7.
• Gude, M.F., Frystyk, J., Flyvbjerg, A., Bruun, J.M., Richelsen, B., Pedersen, S.B. (2012). The production and regulation of IGF and IGFBPs in human adipose tissue cultures. Growth Hormone and IGF Research, 22, 200-205
• Guler, H.P., Zapf, J., Schmid, C. (1989). Insulin-like growth factors I and II in healthy man, Estimations of half-lives and production rates. Acta Endocrinologica, 121, 53–758.
• Harish, V. (2015). Theoretical and Computational Studies of Peptides and Receptors of the Insulin Family. Membranes, 5, 48-83.
• Haywood, N.J., Slater, T.A., Matthews, C.J., B, Stephen, W.B. (2019). The insulin like growth factor and binding protein family, Novel therapeutic targets in obesity & diabetes. Molecular Metabolism, 19, 86-96.
• Hawkes, C., ve Kar S. (2004). The insulin-like growth factor-II/mannose-6-phosphate receptor, structure, distribution and function in the central nervous system. Brain Research Reviews, 44, 117– 140.
• Heald, A.H., Siddals, K.W., Fraser, W., Taylor, W., Kaushal, K., Morris, J., et al. (2002). Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macro- vascular disease and hypertension in type 2 diabetes. Diabetes, 51, 2629-2636.
• Hjortebjerg, R., & Frystyk, J. (2013). Determination of IGFs and their binding proteins. Best Practice & Research Clinical Endocrinology & Metabolism, 27, 771–78.
• Jones, J.I., & Clemmons, D.R. (1995) Insulin-like growth factors and their binding proteins, biological actions. Endocrine Research, 16, 3–34.
• Lalou, C., Sawamura, S., Segovia, B., Ogawa, Y., Binoux, M. (1997). Proteolytic fragments of insulin-like growth factor binding protein-3, N-terminal sequences and relationships between structure and biological activity. Comptes Rendus de l’Academie Sciences III, 320, 621–628.
• Lee, C.Y., & Rechler, M.M. (1995). A major portion of the 150-kilodalton insulin-like growth factor-binding protein (IGFBP) complex in adult rat serum contains unoccupied, proteolytically nicked IGFBP-3 that binds IGF-II preferentially. Endocrinology, 136, 668–678.
• Lee, P.D., Giudice, L.C., Conover, C.A.P.D. (1997). Insulin-like growth factor binding protein-1, recent findings and new directions. Proceedings of the Society for Experimental Biology and Medicine, 216, 319-357.
• LeRoith, D., Werner, H., Beitner-Johnson, D. (1995) Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Reviews, 16, 143-146.
• Levetown, M. (2002). Modulation of types I and II acute phase reactants with insulin-like growth factor-I/binding protein 3 complex in severely burned children. Critical Care Medicine, 30, 255–257.
• López-Bermejo, A., Khosravi, J., Fernández-Real, J.M., Hwa, V., Pratt, K.L., Casamitjana, R., et al. (2006). Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/ MAC25). Diabetes, 55, 2333- 2339.
• Lu, S., Purohit, S., Sharma, A., et al. (2012). Serum insulin-like growth factor binding protein 6 (IGFBP6) is increased in patients with type 1 diabetes and its complications. International Journal of Clinical and Experimental Medicine, 5, 229-237.
• Maridas, D.E., Demambro, V.E., Le, P.T., Mohan, S., Rosen, C.J. (2018). IGFBP4 is required for adipogenesis and influences the distribution of adipose depots. Endocrine Reviews, 158, 3488-3500.
• Martin, J.L., & Baxter, R.C. (1986). Insulin-like growth factor-binding protein from human plasma, Purification and characterization. Journal of Biological Chemistry, 261, 8754–8760.
• Mazerbourg, S., Callebaut, I., Zapf, J., Mohan, S., Overgaard, M., Monget, P. (2004). Up date on IGFBP-4, regulation of IGFBP-4 levels and functions, in vitro and in vivo. Growth Hormone and IGF Research, 14, 71-84.
• Murphy, L.J., Molnar, P., Lu, X., Huang, H. (1995). Expression of human insulin-like growth factor-binding protein-3 in transgenic mice. Journal of Molecular Endocrinology. 15, 293–303.
• Nedic, O., & Masnikosa, R. (2008). The change in the circulating insulin-like growth factor binding protein 1 isoform pattern during the course of oral glucose tolerance test. Metabolism 57,658-661.
• Nissley, P., & Kiess, W. (1991). Reciprocal modulation of binding of lysosomal enzymes and insulin-like growth factor-II (IGF-II) to the mannose 6-phosphate/IGF-II receptor. Advances in Experimental Medicine and Biology, 293, 311-324.
• Okajimina, T., Iwashita, M., Takeda, Y. (1993). Inhibitory effects insulin-like growth factor binding proteins 1 and 3 on IGF activated glucose consumption in mouse Balb/c3T3 fibroblasts. Journal of Endocrinology, 133, 457– 470.
• Raipathak, S.N. (2012). Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes, 61, 2248–2254
• Ranke, MB. Emeritus. (2015). Insulin-like growth factor binding-protein-3 (IGFBP-3). Best Practice & Research Clinical Endocrinology & Metabolism, 29, 701-711.
• Rechler, M.M. (1993). Insulin-like Growth Factor Binding Proteins. Vitamins & Hormones, 47, 1-114.
• Rechler, M.M., & Clemmons, D.R. (1998). Regulatory Actions of Insulin-like Growth Factor-binding Proteins. Technology, Education, Management, Informatics Journal, 9, 176-183.
• Rinderknecht, E., & Humbel, R.E. (1978a). Primary structure of human insulin-like growth factor II., FEBS Letters, 89, 283-286.
• Rinderknecht, E., & Humbel, R.E. (1978b). The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. Journal of Biological Chemistry. 253, 2769-2776.
• Rogol, A.D., Jacobson, W., Smith A. A. (2002). The double-blind, randomized, placebo-controlled, study to determine the döşe response profile of rhIGF-I/rhIGFBP-3 in subjects with Type 2 Diabetes Mellitus requiring insulin therapy. Poster American Diabetes Association. 61.
• Salmon, W.D., & Daughaday W.H. (1957). A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. Journal of Laboratory and Clinical Medicine, 49, 825-836
• Savage, M.O., Camacho-Hübner, C., Dunger, D.B. (2004). Therapeutic applications of the insulin-like growth factors. Growth Hormone & IGF Research, 14, 301–308.
• Schneider, M.R., Wolf, E., Hoeflich, A., Lahm, H. (2002). IGF-binding protein- 5, flexible player in the IGF system and effector on its own. Journal of Endocrinology, 172, 423-440.
• Shimasaki, S., & Ling , N., (1991). Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1,-2, -3, -4, -5 and -6). Progress in Growth Factor Research, 3, 243-266.
• Thrailkill, K.M. (2000). Insulin-like growth factor-I in diabetes mellitus, its physiology, metabolic effects, and potential clinical utility. Diabetes Technology& Therapeutics, 2, 69–80.
• Twigg, S.M., & Baxter, R.C. (1998). Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit. Journal of Biological Chemistry, 273, 6074–6079.
• Vivilan, H., Youngman, O.H., Rosenfeld, R.G. (1999). The Insulin-Like Growth Factor- Binding Protein(IGFBP) Superfamily. The Endocrine Society. 20, 761–787.
• Wang, Y., Nishida, S., Sakata, T., Elalieh, H.Z., Chang, W., Halloran, B.P., Doty, S.B., Bikle, D.D. (2006). Insulin-Like Growth Factor-I Is Essential for Embryonic Bone Development. The Endocrine Society, 47, 4753–476.
• Wheatcroft, S.B., Kearney, M.T., Shah, A.M., Ezzat, V.A., JR Miell, M., Modo, et al. (2007). IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes, 56, 285-294.
• Wild, S., Roglic, G., Green, A., Sicree, R., King, H. 2004. Estimates for the year 2000 and projections for 2030. Diabetes Care, 27,1047-1053.
• Wood, WI et al. (1988). Cloning and expression of the growth hormone-dependent insulin-like growth factor-binding protein. Molecular Endocrinology, 2, 1176–1185.
• Yamada PM, Lee K. (2009). Perspectives in mammalian IGFBP-3 biology, local vs. systemic action. American Journal Physiology- Cell Physiology, 296, 954–976.
• Yau, S.W., Harcourt, B.E. (2018). Serum IGFBP-2 levels are associated with reduced insulin sensitivity in obese children. Clinical Obesity, 8,184-190.
• Zandbergen, A.A. (2006). The IGF-I system and the renal and hemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus, a randomized clinical trial. Clinical Endocrinology, 64, 203–208.
• Zapf, J. (1995). Insulin like growth factor binding proteins and tumor hypoglycemia. Trends in Endocrinology and Metabolism, 6, 37–42.
• Zhao, D., Shen, L., Wei, Y., Xie, J., Chen, S., Liang, Y., et al. (2017). Identification of candidate biomarkers for the prediction of gestational diabetes mellitus in the early stages of pregnancy using iTRAQ quantitative proteomics. Proteomics Clinical Applications, 7-8.